key: cord-0989510-0t9b0c6z
authors: Li, Jing; Zaslavsky, Maxim; Su, Yapeng; Sikora, Michael J.; van Unen, Vincent; Christophersen, Asbjørn; Chiou, Shin-Heng; Chen, Liang; Li, Jiefu; Ji, Xuhuai; Wilhelmy, Julie; McSween, Alana M.; Palanski, Brad A.; Aditya Mallajosyula, Venkata Vamsee; Dhondalay, Gopal Krishna R.; Bhamidipati, Kartik; Pai, Joy; Kipp, Lucas B.; Dunn, Jeffrey E.; Hauser, Stephen L.; Oksenberg, Jorge R.; Satpathy, Ansuman T.; Robinson, William H.; Steinmetz, Lars M.; Khosla, Chaitan; Utz, Paul J.; Sollid, Ludvig M.; Heath, James R.; Fernandez-Becker, Nielsen Q.; Nadeau, Kari C.; Saligrama, Naresha; Davis, Mark M.
title: Human KIR+CD8+ T cells target pathogenic T cells in Celiac disease and are active in autoimmune diseases and COVID-19
date: 2021-12-25
journal: bioRxiv
DOI: 10.1101/2021.12.23.473930
sha: 980bc9709c6466fc17215398a29ea4d6b0782e32
doc_id: 989510
cord_uid: 0t9b0c6z

Previous reports show that Ly49+CD8+ T cells can suppress autoimmunity in mouse models of autoimmune diseases. Here we find a markedly increased frequency of CD8+ T cells expressing inhibitory Killer cell Immunoglobulin like Receptors (KIR), the human equivalent of the Ly49 family, in the blood and inflamed tissues of various autoimmune diseases. Moreover, KIR+CD8+ T cells can efficiently eliminate pathogenic gliadin-specific CD4+ T cells from Celiac disease (CeD) patients’ leukocytes in vitro. Furthermore, we observe elevated levels of KIR+CD8+ T cells, but not CD4+ regulatory T cells, in COVID-19 and influenza-infected patients, and this correlates with disease severity and vasculitis in COVID-19. Expanded KIR+CD8+ T cells from these different diseases display shared phenotypes and similar T cell receptor sequences. These results characterize a regulatory CD8+ T cell subset in humans, broadly active in both autoimmune and infectious diseases, which we hypothesize functions to control self-reactive or otherwise pathogenic T cells. One-Sentence Summary Here we identified KIR+CD8+ T cells as a regulatory CD8+ T cell subset in humans that suppresses self-reactive or otherwise pathogenic CD4+ T cells.

T cells can efficiently eliminate pathogenic gliadin-specific CD4 + T cells from Celiac disease 10 (CeD) patients' leukocytes in vitro. Furthermore, we observe elevated levels of KIR + CD8 + T cells, but not CD4 + regulatory T cells, in COVID-19 and influenza-infected patients, and this correlates with disease severity and vasculitis in COVID-19. Expanded KIR + CD8 + T cells from these different diseases display shared phenotypes and similar T cell receptor sequences. These results characterize a regulatory CD8 + T cell subset in humans, broadly active in both autoimmune and 15 infectious diseases, which we hypothesize functions to control self-reactive or otherwise pathogenic T cells.

Here we identified KIR + CD8 + T cells as a regulatory CD8 + T cell subset in humans that suppresses self-reactive or otherwise pathogenic CD4 + T cells. While most CD8 + T cells are geared towards the control of pathogen-infected or cancerous cells, there have been long standing evidence in mice that a small subset can also suppress autoimmune responses (1). This regulatory function of CD8 + T cells was first implicated by the depletion of CD8 + T cells in experimental autoimmune encephalomyelitis (EAE), a mouse model of human Multiple Sclerosis (MS) (2, 3). In particular, Cantor and colleagues showed that in B6.Qa-1-5 D227K mice, disruption of Qa-1-CD8 coreceptor binding leads to spontaneous autoimmune diseases (4, 5) . The inhibitory C-type lectin-like family of receptors, Ly49, which are ubiquitous on natural killer (NK) cells, were identified as unique surface markers for this regulatory CD8 + T cell subset (6) , and the transcription factor Helios as an essential control element for their differentiation and function in mice (7) . Recently, our group found that clonally expanded CD8 + 10 T cells in EAE recognized peptides bound to H2-D b and that these peptides stimulated Ly49 + CD8 +

Qa-1 to encompass classical class I MHC interactions, as does the results of Sheng et al. (9) , suggesting a general mechanism of peripheral tolerance. Here, we identify CD8 + T cells expressing inhibitory Killer cell Immunoglobulin like Receptors (KIR), the functional counterpart of the 15 mouse Ly49 family in humans (10), as a regulatory CD8 + T cell subset in humans that suppresses pathogenic CD4 + T cells in Celiac disease (CeD), and likely other autoimmune disorders and infectious diseases as well.

Both mouse Ly49 and human KIR receptors bind to class I MHC molecules, typically having the 20 inhibitory tyrosine-based inhibition motifs (ITIM) in their cytoplasmic tails, and are ubiquitously expressed on NK cells, as well as a small subset (1~5%) of CD8 + T cells (6, 10) . Because of these similarities, we analyzed CD8 + T cells expressing inhibitory KIRs (hereby designated as KIR + CD8 + T cells) (11, 12) in the peripheral blood of patients with autoimmune diseases and 5 age/gender-matched healthy controls (HC). Since CD3 + CD56 + cells are likely NKT cells which might have a very different antigen recognition mechanism compared to CD8 + T cells, we only focused on the conventional CD8 + T cells by gating on CD3 + CD56 -TCRαβ + CD8 + cells in this study. KIR3DL1 and KIR2DL3 are the two major KIR subtypes expressed by a small subset of human CD8 + T cells ( fig. S1 ). This normally very small subset (1-2%) of KIR + CD8 + T cells were 5 significantly increased in the blood of many patients with MS, Systemic Lupus Erythematosus (SLE) or CeD, as compared to healthy controls (Fig. 1A) .

Next, we investigated whether KIR + CD8 + T cells are also present in the inflamed tissues of patients with these diseases. We first analyzed the frequency of KIR + CD8 + T cells in the intestinal biopsies of CeD patients in remission or with active disease, as well as in healthy controls. Patients 10 with active disease had higher levels of KIR + CD8 + T cells in the gut than those in remission (on a gluten-free diet) as well as the non-celiac controls (Fig. 1B) , indicating a synchronous expansion of KIR + CD8 + T cells with incidence of autoimmune responses. In addition, we took advantage of publicly available single cell RNA-seq data from SLE kidneys and Rheumatoid Arthritis (RA) synovia previously generated by the Accelerating Medicines Partnership RA/SLE program (13, 15 14) . A markedly increased number of CD8 + T cells expressing KIR transcripts (KIR3DL1, KIR2DL3 and KIR2DL2) was observed in the kidneys of patients with SLE compared to healthy kidneys (Fig. 1C ). In addition, we detected a higher frequency of KIR + CD8 + T cells in the synovial tissues of RA patients compared to those with Osteoarthritis (OA), while the percentages of synovial FOXP3 + CD4 + regulatory T (Treg) cells were similar between RA and OA (Fig. 1D ).

Although both RA and OA cause joint inflammation, RA is a classic autoimmune disease (15), whereas OA is not, suggesting that induction of KIR + CD8 + T cells rather than CD4 + Tregs is more specific to autoimmune inflammations. KIR + CD8 + T cells are the functional and phenotypic equivalent of mouse Ly49 + CD8 + T cells 6 Next we sought to investigate whether KIR + CD8 + T cells are the functional counterpart of mouse Ly49 + regulatory CD8 + T cells. Previously we found that Ly49 + CD8 + T cells suppress myelin oligodendrocyte glycoprotein (MOG)-specific pathogenic CD4 + T cells in a perforin-dependent manner (8), as also suggested by Cantor and colleagues (6) , indicating cytotoxicity as the mechanism of suppression. Deamidated gliadin derived from dietary gluten is the antigen for CD4 + 5 T cells that drive autoimmune enteropathy in human CeD (16, 17) . Therefore, we explored whether KIR + CD8 + T cells can suppress gliadin-specific CD4 + T cells from CeD patients. CD8 + T cells were purified from peripheral blood mononuclear cells (PBMCs) of HLA-DQ2.5 + CeD patients; from these KIR + CD8 + and KIR -CD8 + T cells were sorted, activated with anti-CD3/CD28 microbeads overnight, and then cultured with the CD8-depleted fraction of PBMCs at a 1:30 ratio 10 in the presence of 250μg/mL deamidated gluten. The cultures were harvested on Day 6, and the gliadin-specific CD4 + T cells were enriched and quantified using PE-labeled HLA-DQ2.5 tetramers complexed with different gliadin peptides ( Fig. 2A) (18, 19) . In the absence of KIR + CD8 + T cells, deamidated gluten profoundly stimulated the expansion of gliadin-specific CD4 + T cells. Importantly, stimulated KIR + CD8 + T cells, but not KIR -CD8 + T cells or KIR + NK 15 cells , significantly reduced the number of gliadin-specific CD4 + T cells ( Fig. 2B and fig. S2B ) without affecting the number of total CD4 + T cells ( fig. S2A ). This effect of KIR + CD8 + T cells appears to target only the pathogenic CD4 + T cells, since they had no discernible effect on hemagglutinin (HA)-specific CD4 + T cells induced by influenza A HA peptides ( fig. S2C ) or on proliferation of CD4 + T cells responding to anti-CD3 stimulation ( fig. 2D ). We also measured 20 Annexin V binding on Day 3 ( Fig. 2A) and found increased staining of gliadin-specific CD4 + T cells in the presence of KIR + CD8 + T cells (Fig. 2C ), indicating these T cells induce apoptosis of the pathogenic CD4 + T cells. Since previous studies suggest that the regulatory function of mouse Ly49 + CD8 + T cells is mediated by both recognition of H2-D b (classical MHC I) (8) and Qa-1 (non-7 classical MHC I) (5, 6, 9) on their target cells, we investigated whether destruction of gliadinspecific CD4 + T cells by KIR + CD8 + T cells is dependent on their recognition of MHC I. Therefore, we blocked HLA-ABC or HLA-E with specific antibodies in the presence of KIR + CD8 + T cells and determined the frequency of gliadin-specific CD4 + T cells as a readout of the suppressive activity of KIR + CD8 + T cells. Our results show that anti-HLA-ABC blockade partially reversed 5 the suppression by KIR + CD8 + T cells in 4/6 patients, while anti-HLA-E blockade restrained the suppressive functions of KIR + CD8 + T cells in 5/6 patients (p<0.05) (Fig. 2D ). Taken together, our data suggest that KIR + CD8 + T cells specifically eliminate gliadin-specific pathogenic CD4 + T cells from the leukocytes of CeD patients via recognition of classical and/or non-classical MHC I molecules.

To further investigate whether KIR + CD8 + T cells are the phenotypic equivalent of mouse Ly49 + T cells in humans, we performed RNA sequencing (RNA-seq) analysis on KIR + versus KIR -CD8 + T cells from patients with MS to compare with mouse Ly49 + CD8 + T cells in EAE (mouse model of human MS). There were 778 differentially expressed genes (adjusted P<0.05, fold change >2) between KIR + and KIR -CD8 + T cells, among them 300 were up-regulated and 478 were down-15 regulated in KIR + CD8 + T cells (table S1) . Notably, KIR + CD8 + T cells showed a marked upregulation of cytotoxic molecules (e.g. GZMH, GZMB, PRF1 and GNLY), NK-associated genes (e.g. NKG7, NCR1 and the KLR family) and cell-trafficking molecules (such as CX3CR1, which mediates migration of leukocyte to inflamed tissues and is involved in tissue injury-mediated brain inflammation, and brain-homing receptor ITGB1), in addition to inhibitory KIR receptor genes 20 (Fig. 3A ). In addition, KIR + CD8 + T cells had higher transcript levels for Helios (encoded by IKZF2), a transcription factor associated with regulatory functions of both CD4 + and CD8 + T cells (7) . On the other hand, KIR + CD8 + T cells down-regulated naïve/memory T cell-associated molecules, e.g. CCR7, SELL, TCF7 and IL7R, indicating they might have entered the program for 8 effector T cell differentiation. Interestingly, KIR + CD8 + T cells had a lower expression of the costimulatory receptor CD28 (Fig. 3A) , which is one of the key features for regulatory CD8 + T cell populations in mice and humans (20). Gene Ontology enrichment analysis of these differentially expressed genes showed enrichment for T cell activation, proliferation, migration and differentiation (Fig. 3B) . Moreover, gene set enrichment analysis (GSEA) (21, 22) revealed that 5 about half of the top 200 genes up-regulated in Ly49 + CD8 + T cells (including cytotoxic molecule GZMB, KLRC family genes, CX3CR1, ITGB1 and IKZF2) were also higher in KIR + CD8 + T cells (Fig. 3C) . Previously, we found Ly49 + CD8 + T cells expressed 16 out of 60 of the genes conserved in CD4 + Tregs (8), and these same Treg signature genes (23) were also enriched in KIR + CD8 + T cells in GSEA analysis (Fig. 3D) . Overall, RNA-seq analysis indicates that KIR + CD8 + T cells from 10 MS patients share many similarities with Ly49 + CD8 + T cells from EAE mice. Furthermore, we also performed RNA-seq on KIR + and KIR -CD8 + T cells from healthy subjects and patients with other autoimmune diseases, specifically CeD and SLE, to determine whether there are common features shared by KIR + CD8 + T cells across different circumstances. We identified a set of 963 genes that were differentially expressed (adjusted P<0.05, fold change >2) 15 between KIR + and KIR -CD8 + T cells from all subjects, including HC, MS, CeD, and SLE patients. 3B ). In addition, we compared KIR + and KIR -CD8 + T cells in kidneys or synovia for expression of the same genes enriched in circulating KIR + CD8 + T cells.

Similar to those cells, both kidney and synovial KIR + CD8 + T cells up-regulated KLRG1, CD244, 9 TIGIT, CX3CR1, PRF1, GZMB and IKZF2, while down-regulating CD28 and CCR7 ( fig. S4 ).

Overall, our results suggest KIR + CD8 + T cells are the functional and phenotypic equivalent of mouse Ly49 + CD8 + T cells in humans, with conserved features in both healthy subjects and those with autoimmune diseases.

Increased KIR + CD8 + T cells in SARS-CoV-2-and Influenza-infected patients 5 While previously it had been thought that most self-specific T cells were eliminated in the thymus, recent work shows that this is not the case, and that many such cells survive and populate the periphery of both humans and mice (24, 25). We have speculated that this is because the constant threat of infectious diseases throughout human history (26) necessitates a complete T cell repertoire (24, 27) such that even self-reactive T cells might be needed in the response to a 10 particular pathogen. Consistent with this are classic experiments showing that infectious diseases or treatments that mimic them can activate self-specific T cells (28, 29). There is also anecdotal evidence that many patients with autoimmune diseases cite an infection immediately preceding the onset of their disease (30-34). Thus, we were interested in analyzing patients with an infectious disease to see whether KIR + CD8 + T cells were induced as part of the response. In particular, 15 emerging reports show that infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) can lead to excessive production of pro-inflammatory cytokines and autoreactivity is one of the common features of severe disease with pathogenic prothrombotic autoantibodies detected in serum from patients hospitalized with Coronavirus Disease 2019 (COVID-19) (35-39).

Therefore, we analyzed the frequency of KIR + CD8 + T cells in the peripheral blood of patients with 20 COVID-19 as compared to age/gender-matched healthy subjects collected before the pandemic.

The percentage of KIR + CD8 + T cells was elevated in COVID-19 patients and correlated with disease severity (Fig. 4A) . Moreover, an even higher frequency of KIR + CD8 + T cells was found in COVID-19 patients with vasculitis or embolism and to a lesser extent in those with acute 10 respiratory distress syndrome (ARDS) ( Fig. 4B and figs. S5, C-D), which are common complications of this disease and likely caused by excessive inflammation. Therefore, increase of KIR + CD8 + T cells might be indicative for autoimmune-related immunopathology during SARS-CoV-2 infection. However, we did not observe a significant difference in the levels of CD25 hi CD127 low CD4 + Tregs or KIR + NK in COVID-19 patients compared to healthy donors, or (table S3) . These findings reveal the commonality of KIR + CD8 + T cells across physiological and diseased status as well as their uniqueness relative to other CD8 + T cells.

In order to better understand the similarity and heterogeneity of KIR + CD8 + T cells under different circumstances and to probe the mechanism for their suppressive activity to pathogenic 10 CD4 + T cells, we performed single cell RNA-seq on 4,512 KIR + CD8 + T cells sorted from the blood of age-and gender-matched healthy subjects (N=10) and patients with MS (N=2), SLE (N=6) or CeD (N=5) using the Smart-seq2 protocol (44). In parallel, we also analyzed their T-cell receptor (TCR) α and β sequences (45). Unsupervised clustering of these KIR + CD8 + T cells by Seurat To get a comprehensive understanding on the TCR repertoire of KIR + CD8 + T cells, we used the VDJtools (47) to estimate the diversity of KIR + CD8 + TCRs as compared to KIR -CD8 + TCRs from the same individuals (N=26). We found TCRs of KIR + CD8 + T cells had significantly lower Shannon-Wiener Index and chao estimates than that of KIR -CD8 + T cells (Figs. 6, A-B), indicating 15 the TCR repertoire of KIR + CD8 + T cells is less diverse, which is also consistent with the previous report that KIR + CD8 + T cells display a more restricted TCR Vβ chain usage (11) . In order to compare the antigen specificities of KIR + CD8 + T cells from different disease types, we also utilized GLIPH2 (48), which is an algorithm to cluster TCRs that recognize the same antigen in most cases, to analyze single-cell TCR sequences of sorted KIR + (6815 unique TCRs) or KIR -20 CD8 + T cells (1630 unique TCRs) from healthy controls (N=10), MS (N=2), SLE (N=20), CeD (N=5), T1D (N=5) and COVID-19 (N=5) patients and bulk TCRβ sequences of sorted KIR + CD8 + T cells from 9 healthy controls (5607 unique TCRβ) along with their class I HLA alleles. The GLIPH2 analysis generated 982 clusters and 668 of them were shared between any two sources. 13 We further filtered the resulting GLIPH clusters to 62 specificity groups that contained TCRs from 3 or more individuals and exhibited significant bias of V-gene usage (P<0.05) and some of them are shown in Figure 6C . TCRs of KIR + CD8 + T cells from healthy donors and patients with autoimmune diseases or COVID-19 can be grouped into the same GLIPH clusters, although with different extent of clonal expansion, indicating they might recognize same antigens commonly 5 exist under physiological and different pathological conditions. Therefore, expanded KIR + CD8 + T cells have shared phenotypes and antigen specificity independent of the disease types studied here.

While the analysis above shows that the TCR repertoire of KIR + CD8 + T cells is less diverse than CD8 + T cells generally, it is still considerably diverse, utilizing multiple classical HLAs and HLA-E, and probably many antigenic peptides as well. Previously we have found an average of 5 GLIPH 10 clusters for each peptide MHC ligand (49), so there may be 10 or more such ligands for these T cells at a minimum. The identification of these ligands, and whether they extend beyond pathogenic CD4 + T cells will be important to determine in the future.

Here we characterize KIR + CD8 + T cells as a novel regulatory CD8 + T cell subset in humans, which 15 suppress pathogenic CD4 + T cells in CeD, and likely other autoimmune diseases or infectious diseases as well, via their cytolytic activity. Similar to the perforin-or Fas/FasL-dependent suppression of self-reactive CD4 + T cells by murine Ly49 + CD8 + T cells (8, 50), human KIR + CD8 + T cells might also target pathogenic CD4 + T cells via their cytolytic activity, since expanded KIR + CD8 + T cells significantly up-regulated cytotoxic molecules and increased apoptosis in 20 gliadin-specific CD4 + T cells was observed in the presence of KIR + CD8 + T cells. This effect of KIR + CD8 + T cells is specific to self-reactive or otherwise pathogenic T cells, but not CD4 + T cells recognizing foreign antigens, since presence of KIR + CD8 + T cells had no discernable effects on HA-specific CD4 + T cells. In addition, the destruction of pathogenic CD4 + T cells by KIR + CD8 +

T cells appears to depend on recognition of both classical and non-classical I MHC molecules, since the blockade of either HLA-ABC or HLA-E can reverse the suppression by KIR + CD8 + T cells. We often observe an increased frequency of KIR + CD8 + T cells in the blood and also in the inflamed tissues of patients with autoimmune disease, and this positively correlates with disease activity of CeD. This expansion of KIR + CD8 + T cells correlating with the incidence of autoimmune 5 responses might act as a negative feedback mechanism to ameliorate pathogenesis by killing autoreactive T cells. Besides, increased KIR + CD8 + T cells were found in COVID-19 patients and were associated with autoimmune-related complications. These increases were not restricted to SARS-CoV-2 infection, but also observed in patients with influenza virus infection, indicating increase of KIR + CD8 + T cell is a general mechanism induced during an infection. Therefore, we 10 hypothesize that a primary role of KIR + CD8 + T cells might be to control pathogenic T cells that arise from self-reactivity in autoimmune disorders or in the course of an infectious disease owing to their cross-reactivity to antigens expressed by a particular pathogen. This would allow an organism to maintain as complete a peripheral T cell repertoire as possible to protect itself against potential infection by pathogens, yet still be able to precisely control T cell clones with cross-15 reactivity to self antigens. Interestingly, clonally expanded KIR + CD8 + T cells are also found in the peripheral blood of healthy subjects and share gene expression signatures as well as some antigen specificities with those from patients with autoimmune diseases or COVID-19. This indicates that at least some T cells of this type are continually active-although not at the very high levels that we see in COVID-19 patients or in some subjects with autoimmunity. This suggests that the activation 20 of KIR + CD8 + T cells is a specific regulatory mechanism to maintain peripheral tolerance, even in healthy people. This type of peripheral tolerance is distinct from and likely complementary to for the clinical applications of these discoveries. Other co-authors declare that they have no competing interests.

Data and materials availability: Data generated in this study are included within the paper or are available from the corresponding authors upon reasonable request. Raw RNA-seq data that support 23 the findings of this study have been deposited in the Gene Expression Omnibus under the accession number GSE168527. The code used for data analyses in this study are available from the corresponding authors upon reasonable request.

Figs. S1 to S6

References (53-64)

Tables S1 to S6 

New Insights Into the Biology of CD8

Less Mortality but More Relapses in Experimental Allergic Encephalomyelitis in Cd8-/-Mice

Role of Cd8+ T-Cells in Murine Experimental Allergic Encephalomyelitis

Regulation of self-tolerance by Qa-1-restricted CD8(+) regulatory 15 T cells

Inhibition of follicular T-helper cells by CD8(+) regulatory T cells is essential for self tolerance

CD8+ T regulatory cells express the Ly49 Class I MHC receptor and are defective in autoimmune prone B6-Yaa mice

Stable inhibitory activity of regulatory T cells requires the transcription factor Helios

Opposing T cell responses in experimental autoimmune encephalomyelitis

Distinct PLZF(+)CD8alphaalpha(+) Unconventional T Cells Enriched in Liver Use a Cytotoxic Mechanism to Limit Autoimmunity

Ly49 receptors: evolution, genetic diversity, and impact on immunity

CD8 T cells express randomly selected KIRs with distinct specificities compared with NK cells

Human KIR2DL5 is an inhibitory receptor expressed on the surface of 10 NK and T lymphocyte subsets

The immune cell landscape in kidneys of patients with lupus nephritis

Defining inflammatory cell states in rheumatoid arthritis joint synovial tissues by integrating single-cell transcriptomics and mass cytometry

The pathogenesis of rheumatoid arthritis

Integration of genetic and immunological insights into a model of celiac disease pathogenesis

Identification of a gliadin T-cell epitope in coeliac disease: general importance of gliadin deamidation for intestinal T-cell recognition